ArticleJournal of biological engineering2026
A thermosensitive hydrogel delivery system incorporating wogonin-treated mesenchymal stromal cell (MSC)-derived exosomes alleviates osteoarthritis.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a prevalent degenerative joint disease affecting major joints, causing pain and functional impairment due to cartilage degeneration and osteophyte formation. Current treatments have significant limitations. Mesenchymal stromal cell (MSC)-based therapy is advantageous for its regenerative and immunomodulatory properties, with the infrapatellar fat pad (IPFP) being a reliable MSC source involved in knee osteoarthritis (KOA) progression. MSC-derived exosomes (MSCs-Exo) are key for therapeutic efficacy through paracrine actions but face rapid clearance by the reticuloendothelial system. Sustained release drug delivery systems based on biodegradable biomaterials could enhance MSCs-Exo retention and control their release, promoting tissue repair. Previous studies indicate that wogonin, a natural flavonoid from Scutellaria baicalensis, can stimulate MSCs and be associated with enhanced therapeutic efficacy of MSCs-Exo. This study develops a thermosensitive hydrogel delivery system for intra-articular injection, incorporating IFP-MSCs-Exo (Gel@MSC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.